Sanara Medtech Inc
NASDAQ:SMTI
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
26.86
41.6
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Sanara Medtech Inc
Net Income (Common)
Sanara Medtech Inc
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Sanara Medtech Inc
NASDAQ:SMTI
|
Net Income (Common)
-$8.4m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
-9%
|
||
Haemonetics Corp
NYSE:HAE
|
Net Income (Common)
$123.8m
|
CAGR 3-Years
58%
|
CAGR 5-Years
13%
|
CAGR 10-Years
15%
|
||
ICU Medical Inc
NASDAQ:ICUI
|
Net Income (Common)
-$111m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Align Technology Inc
NASDAQ:ALGN
|
Net Income (Common)
$441.6m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
1%
|
CAGR 10-Years
12%
|
||
Lantheus Holdings Inc
NASDAQ:LNTH
|
Net Income (Common)
$427.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
65%
|
CAGR 10-Years
N/A
|
||
Merit Medical Systems Inc
NASDAQ:MMSI
|
Net Income (Common)
$120m
|
CAGR 3-Years
40%
|
CAGR 5-Years
45%
|
CAGR 10-Years
19%
|
Sanara Medtech Inc
Glance View
Sanara MedTech, Inc.engages in the development, marketing, and distribution of biotechnology products to physicians, hospitals, and clinics. The company is headquartered in Fort Worth, Texas and currently employs 63 full-time employees. The Company’s products include surgical wound care products, which includes CellerateRX Surgical Activated Collagen (Powder and Gel), and chronic wound care products, which include HYCOL Hydrolyzed Collagen (Powder and Gel), BIAKOS Skin and Wound Cleanser and BIAKOS Skin and Wound Gel. The surgical wound care products are used in specialties including cardiothoracic, colorectal, general surgery, hand, head and neck, high-risk obstetrics and gynecology, Mohs surgery, neurosurgery, oncology, plastic/reconstructive, podiatric, urology and vascular. The chronic wound care products are used across the post-acute continuum of care, including home health, hospice, physician offices, podiatrists, retail, skilled nursing facilities, and wound care centers.
See Also
What is Sanara Medtech Inc's Net Income (Common)?
Net Income (Common)
-8.4m
USD
Based on the financial report for Sep 30, 2024, Sanara Medtech Inc's Net Income (Common) amounts to -8.4m USD.
What is Sanara Medtech Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-9%
Over the last year, the Net Income (Common) growth was -2%. The average annual Net Income (Common) growth rates for Sanara Medtech Inc have been -22% over the past three years , -35% over the past five years , and -9% over the past ten years .